Academic Journal
Q1Annals of the Rheumatic Diseases
About Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases is a scholarly journal published by Elsevier B.V.. SCImago 2025 places it in Q1 with an SJR of 7.286 and an H-index of 315.
Its listed coverage is 1945-1948, 1950-2026 and its research categories include Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1); Immunology (Q1); Immunology and Allergy (Q1); Rheumatology (Q1). The 2025 dataset reports 333 documents and 10708 citations across the latest three-year reporting window.
Elsevier B.V. is one of the world’s leading providers of scientific, technical, and medical information. Headquartered in Amsterdam, Netherlands, Elsevier has played a central role in advancing knowledge and innovation since its founding in 1880. As a major part of the RELX Group, Elsevier B.V. supports the global research community through high-quality academic publishing and cutting-edge digital solutions.
A Trusted Name in Academic and Scientific Publishing
Elsevier publishes more than 2,700 peer-reviewed academic journals, including some of the most prestigious titles in science and medicine such as The Lancet, Cell, and Physics Reports. These journals cover a wide range of disciplines including life sciences, physical sciences, social sciences, engineering, and healthcare. Each year, Elsevier contributes to the publication of over 430,000 research articles, helping researchers share discoveries, validate findings, and push the boundaries of knowledge.
Digital Transformation and Innovation
In recent years, Elsevier B.V. has shifted focus toward digital transformation, making scientific content more accessible and easier to use. Platforms like ScienceDirect, Scopus, and Mendeley are widely used by researchers, educators, and students to access research articles, track citations, manage references, and collaborate across disciplines.
-
ScienceDirect offers millions of full-text scientific articles across hundreds of subject areas.
-
Scopus is a comprehensive abstract and citation database used for tracking research impact and trends.
-
Mendeley is a reference manager and academic social network that helps researchers manage and share research papers.
These tools not only enhance the publishing process but also enable users to discover, analyze, and apply scientific knowledge more efficiently.
Supporting the Research Community
Elsevier B.V. is committed to supporting the global research community through various initiatives that promote open science, diversity, and ethical publishing. The company has launched multiple open access options, allowing researchers to make their work freely available to readers worldwide. Through its open science initiatives, Elsevier promotes transparency, reproducibility, and public access to scientific research.
Additionally, Elsevier offers data analytics and research performance tools to academic institutions, governments, and corporations. These services help stakeholders make informed decisions and invest wisely in research and development.
Ethical Standards and Peer Review
Maintaining high ethical standards is a core value at Elsevier. The company enforces strict peer review processes and publishing ethics to ensure the integrity and credibility of the research it disseminates. It partners with editorial boards and subject matter experts to maintain quality and fairness in publishing.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Elsevier B.V. is a renowned name in the world of academic publishing, recognized globally for its wide scope of contributions to science, technology, and health research. Headquartered in Amsterdam, Netherlands, Elsevier is part of the RELX Group and plays a pivotal role in the dissemination of peer-reviewed scientific knowledge. But what exactly is the scope of Elsevier B.V. and why is it so influential?
The Broad Scope of Elsevier’s Publishing Platform
Elsevier publishes over 2,700 scientific journals and more than 35,000 book titles, covering a vast array of disciplines. From life sciences and physical sciences to engineering, social sciences, and clinical medicine, Elsevier's scope spans almost every branch of academic study. Journals such as The Lancet, Cell, and ScienceDirect are among the most cited and respected in their fields.
Its digital platforms, including ScienceDirect, Scopus, and Mendeley, serve as vital tools for researchers, students, and institutions. These platforms offer access to millions of articles, datasets, and analytics, making Elsevier a cornerstone of modern academic research.
Research and Innovation at the Core
One of the defining features of Elsevier B.V. is its commitment to innovation. The company invests heavily in AI, data analytics, and advanced publishing technology to improve research workflows and facilitate better decision-making. Elsevier also supports open access publishing, allowing authors to make their research freely available to the public through a variety of models.
Through tools like Scopus, Elsevier not only indexes a wide range of peer-reviewed literature but also provides citation analysis and impact metrics. This data-driven approach helps scholars evaluate the significance and reach of their work.
Supporting Global Academic Communities
Elsevier’s scope isn’t limited to publishing alone. The company actively collaborates with universities, research institutions, libraries, and government organizations worldwide. By hosting conferences, funding research initiatives, and promoting diversity and inclusion in science, Elsevier fosters a collaborative global research community.
Furthermore, Elsevier has implemented ethical publishing guidelines and transparency policies to maintain the integrity of scholarly communication. Their rigorous peer-review process ensures that only high-quality, credible work is published under their name.
Why the Scope of Elsevier B.V. Matters
In an era where information is abundant, the scope of Elsevier B.V. ensures that academic and scientific data are accessible, reliable, and well-curated. Whether you're a researcher looking for high-impact journals, a librarian managing digital access, or a policymaker using data to shape the future—Elsevier has something for you.
Recent Research Articles
Latest publications matched automatically by ISSN.
Response to correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
Tommy K. Annfeldt, Tobias Haugegaard, Laura C. Coates, Ana-Maria Orbai et al.
2026-09 · DOI: 10.1016/j.ard.2026.07.008CNS immune remodelling in SLE associated with anti-CD19 CAR-T therapy
Jinjian Sun, Xiaoru Hu, Weina Li, Zuge Tian et al.
2026-09 · DOI: 10.1016/j.ard.2026.06.030Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis—a case series
Laura Bucci, Melanie Hagen, Sebastian Böltz, Carlo Tur et al.
2026-09 · DOI: 10.1016/j.ard.2026.07.011Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis
Maithri Aspari, Voon Ong, Klaus Søndergaard, Esben Næser et al.
2026-09 · DOI: 10.1016/j.ard.2026.01.008Correspondence on ‘Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study’ by Mysler et al
Wenpeng Zhang, Yiwen Ding, Xiaowei Zhang, Meng Dong et al.
2026-09 · DOI: 10.1016/j.ard.2026.04.014Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals
Imke Redeker, Maria Zacharopoulou, Andrea Schmidt, Uta Kiltz et al.
2026-09 · DOI: 10.1016/j.ard.2026.08.005Automated detection of active and structural MRI lesions in the sacroiliac joints in axial spondyloarthritis: training and validation across 3 phase III clinical trial datasets
Amir Jamaludin, Rhydian Windsor, Sarim Ather, Andrew Zisserman et al.
2026-09 · DOI: 10.1016/j.ard.2026.08.003Response to ‘Correspondence on “Results of a 1-year randomized double-blind placebo-controlled trial with methotrexate 25 mg/week in recently diagnosed polymyalgia rheumatica” by Bolhuis TE et al’
Noortje E.S.E.P. Kooijman, Nathan den Broeder, Alfons A. den Broeder, Aatke van der Maas et al.
2026-09 · DOI: 10.1016/j.ard.2026.05.027Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025
Kevin L. Winthrop, Andreas Kerschbaumer, John D. Isaacs, Philip Mease et al.
2026-09 · DOI: 10.1016/j.ard.2026.03.024Proinflammatory autoantibodies enhancing tumor necrosis factor and RANKL signaling in axial spondyloarthritis associate with hyperphosphorylated progranulin and osteoprotegerin
Zanir Abdi, Natalie Fadle, Evi Regitz, Igor Age Kos et al.
2026-09 · DOI: 10.1016/j.ard.2026.04.008Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy
Teresa Preglej, Anela Tosevska, Marie Brinkmann, Philipp Schatzlmaier et al.
2026-09 · DOI: 10.1016/j.ard.2026.05.018Novel HLA class I and II insights into the pathogenesis of systemic sclerosis–associated interstitial lung disease
Carlos Rosa-Baez, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, Gonzalo Borrego-Yaniz et al.
2026-09 · DOI: 10.1016/j.ard.2026.05.004Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Deanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, Maria E Suarez-Almazor et al.
2026-09 · DOI: 10.1016/j.ard.2026.02.017Mitochondrial-impaired ductal epithelium fuels TLS formation in Sjögren’s disease
Yuan Zong, Yi Yang, Jiawen Zhao, Shiyi Wen et al.
2026-09 · DOI: 10.1016/j.ard.2026.05.014Blinatumomab in refractory SLE-associated immune thrombocytopenia
Elpida Phithak, Robert Biesen, Fredrik N Albach, Victoria Boeckel et al.
2026-09 · DOI: 10.1016/j.ard.2026.08.004Bilirubin regulating the onset of rheumatoid arthritis
Nadine Otterbein, Klara Martinsson, Eva Schmid, Lukas Heinen et al.
2026-09 · DOI: 10.1016/j.ard.2026.03.014Functional insights into autoantibodies targeting muscarinic acetylcholine receptors in Sjögren’s disease
Fiona Engelke, Harald Heidecke, Kai Schulze-Forster, Heike Bähre et al.
2026-09 · DOI: 10.1016/j.ard.2026.06.016Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries
Louise Majormoen Nielung, Daniela Di Giuseppe, Merete Lund Hetland, Johan Askling et al.
2026-09 · DOI: 10.1016/j.ard.2026.08.002Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behçet’s disease
Elio Carmona, Rabia Deniz, Cemal Bes, Haner Direskeneli et al.
2026-09 · DOI: 10.1016/j.ard.2026.06.033SDH inhibition quenches rheumatoid arthritis flare-associated IL-1β+IFN-γ+ macrophages via NF-κB/STAT4
Stephanie R. Zack, Neha Satoeya, Víctor Andrés Sosa Hernández, Sania Deen et al.
2026-09 · DOI: 10.1016/j.ard.2026.07.025Reviews
Community Reviews
Version History
April 20, 2025 at 4:08 am
April 20, 2025